Article Epilepsy Patients Pharmaceutical 
CannaTech
JANUARY 16, 2019
Thanks to the recent emergence of regulated medical cannabis markets, the success of this versatile plant can be followed from farm to pharma and prescriber to patient, however, the origins of cannabis as medicine cannot be as simply traced as the plant is today from seed to sale. Of course, patients need product and product costs money.
Cannabis Law Report
JANUARY 15, 2019
British firm GW Pharmaceuticals is licking its wounds after US judges tossed out its attempt to patent multiple cannabinoids for epilepsy treatment following an eight-year battle. The patent, which has been embroiled in dispute since 2010, is for “the use of one or more cannabinoids in the treatment of epilepsy”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MMJ Recs
NOVEMBER 20, 2023
This article delves into the science behind medical marijuana, focusing on cannabinoids, the active compounds found in the cannabis plant, and their remarkable therapeutic effects. Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition.
Canna Law Blog
MARCH 12, 2019
9,066,920 – “Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy” (“the 920 Patent”). GW Pharma”) and Otsuka Pharmaceuticals Co., Epidiolex was approved to treat two rare forms of epilepsy: Dravet syndrome and Lennox-Gastaut syndrome. In this case, the subject patent was U.S.
CannaMD
JULY 14, 2020
Polypharmacy is a growing problem where patients are prescribed multiple different medications simultaneously in order to treat a given medical condition. It’s often mistakenly believed that taking multiple medications results in better management of a patient’s symptoms, but often that’s simply not the case. WHAT IS POLYPHARMACY?
MMJ Recs
NOVEMBER 17, 2023
This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has the potential to reduce opioid dependence and addiction, leading to safer and healthier communities.
Project CBD
FEBRUARY 28, 2023
5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Available at: www.ncbi.nlm.nih.gov/pmc/articles/PMC7400098/.
Expert insights. Personalized for you.
89 
Let's personalize your content